Silexion Therapeutics Corp. (SLXN)
2.57
-0.17
(-6.20%)
USD |
NASDAQ |
Jul 08, 13:56
Silexion Therapeutics Debt to Equity Ratio : 6.835 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 6.835 |
| December 31, 2025 | 0.7822 |
| September 30, 2025 | 0.2902 |
| June 30, 2025 | 30.82 |
| March 31, 2025 | 1.346 |
| December 31, 2024 | -1.126 |
| September 30, 2024 | -0.9417 |
| June 30, 2024 | 1.318 |
| March 31, 2024 | 1.176 |
| December 31, 2023 | -0.4081 |
| September 30, 2023 | 0.7942 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0837 |
| March 31, 2023 | 0.0641 |
| December 31, 2022 | 0.0103 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| BioLineRx Ltd. | 0.544 |
| Kamada Ltd. | 0.0449 |
| Can-Fite BioPharma Ltd. | -- |
| Galmed Pharmaceuticals Ltd. | 0.00 |
| Revium Recovery, Inc. | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 4.602M |
| Total Liabilities (Quarterly) | 4.311M |
| Shareholders Equity (Quarterly) | 0.291M |
| Current Ratio | 1.001 |
| Net Debt Paydown Yield | 12.50% |